RAGE and cardiovascular disease

Frontiers in Bioscience

Volumn 16, Issue 2, 2011, Pages 486-497

  Park, Sungha ^a   Yoon, Se Jung ^c   Tae, Hyun Jin ^b   Shim, Chi Young ^a  

^a Yonsei University College of Medicine   (South Korea)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c National Health Insurance Corporation   (South Korea)

Author keywords

Atherosclerosis; Cardiovascular disease; Inflammation; RAGE; Review; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; AUTACOID; BIOLOGICAL MARKER; CALGRANULIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN RECEPTOR;

ABDOMINAL AORTA ANEURYSM; ANIMAL; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; DIABETIC ANGIOPATHY; HUMAN; HYPERTENSION; INFLAMMATION; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION INJURY; REVIEW; SOLUBILITY; VASCULAR RESISTANCE;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETIC ANGIOPATHIES; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; HYPERTENSION; INFLAMMATION; INFLAMMATION MEDIATORS; LEUKOCYTE L1 ANTIGEN COMPLEX; MICE; MYOCARDIAL REPERFUSION INJURY; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC; SOLUBILITY; VASCULAR RESISTANCE;

EID: 79955029506     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3700     Document Type: Article

References (106)

1. Ridker PM, Buring JE, Rifai N, Cook NR: Development and validation of improved algorithm for the assessment of global cardiovascular risk in women. JAMA 297, 611-9 (2007)
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352, 1685-95 (2005)
3. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH Jr, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities Study. Arch Intern Med 166, 1368-73 (2006) (Pubitemid 44036348)
4. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198 (10), 1507-15 (2003) (Pubitemid 37467165)
5. Lin, L: RAGE on the Toll Road? Cell Mol Immunol 3 (5), 351-8 (2006)
6. Lin L, Park S, Lakatta EG: RAGE signaling and arterial aging. Front Biosci 14, 1403-13 (2009)
7. Herold K, Moser B, Chen Y, Zeng S, Yan SF, Ramasamy R, Emond J, Clynes R, Schmidt AM: Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol 2007, 82 (2), 204-12 (2007) (Pubitemid 47230628)
8. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Münch G: Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 92 (2), 255-63 (2005) (Pubitemid 40194017)
9. Harris HE, Raucci A: Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep 7 (8), 774-8 (2006) (Pubitemid 44275393)
10. Matzinger P: Friendly and dangerous signals: is the tissue in control? Nat Immunol 8 (1), 11-3 (2007) (Pubitemid 46242350)
11. Thornalley PJ, Langborg A, Minhas HS: Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344, 109-16 (1999)
12. Thornalley PJ: Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation endproducts (RAGE)-an introduction. Mol Nutr Food Res 51 (9), 1107-10 (2007) (Pubitemid 47522803)
13. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H: Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62 (4), 427-33(2007) (Pubitemid 47065712)
14. Yan SF, Ramasamy R, Schmidt AM: Mechanisms of disease: advanced glycation endproducts and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4 (5), 285-293 (2008) (Pubitemid 351571138)
15. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A, Antonio Migheli A, Stern D: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143(6), 1699-712 (1993) (Pubitemid 24058273)
16. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signaling suppresses tumour growth and metastases. Nature 405, 354-60 (2000) (Pubitemid 30337069)
17. Hoffmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901 (1999) (Pubitemid 29375048)
18. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, Ballantyne CM, Gahmberg CG, Bianchi ME, Nawroth PP, Chavakis T: A novel pathway of HMGB1- mediated inflammatory cell recruitment that requires Mac-1- integrin. EMBO J 26, 1129-39 (2007)
19. Chavakis T, Bierhaus A, Nawroth PP: RAGE (receptor for advanced glycation endproducts): a central player in the inflammatory response. Microbes Infect, 6, 1219-25 (2004) (Pubitemid 39370091)
20. Yan SF, Ramasamy R, Naka Y, Schmidt AM: Glycation, inflammation and RAGE. A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 93, 1159-69 (2003) (Pubitemid 37543056)
21. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: N (epsilon)- (carboxymethyl) lysine adducts of proteins are ligands for RAGE that activate cell signaling pathways and modulate gene expression. J Biol Chem 274, 31740-9 (1999)
22. Huang JY, Guh JY, Chen HC, Hung WC, Lai YH, Chuang LY: Role of receptor for advanced glycation endproduct (RAGE) and the JAK/STAT signaling pathway in AGE induced collagen production in NRK-49F cell. J Cell Biochem 81, 102-113 (2001)
23. Hirose A, Tanikawa T, Mori H, Okada Y, Tanaka Y: Advanced glycation end products increase endothelial permeability through RAGE/Rho signaling pathway. FEBS Lett 584 (1), 61-66 (2010)
24. Touré F, Zahm J, Garnotel R, Lambert E, Bonnet N, Schmidt AM, Vitry F, Chanard J, Gillery P, Rieu P: Receptor for advanced glycation endproducts (RAGE) modulates neutrophil adhesion and migration on glycoxidated extracellular matrix. Biochem J 416, 255-261 (2008)
25. Coughlan MT, Thorburn DR, Penfold SA, Laskowski A, Harcourt BE, Sourris KC, Tan ALY, Fukami K, Thallas- Bonke V, Nawroth PP, Brownlee M, Bierhaus A, Cooper ME, Forbes JM: RAGE induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20, 742-752 (2009)
26. Liu Y, Liang C, Liu X, Liao B, Pan X, Ren Y, Fan M, Li M, He Z, Wu J, Wu Z: AGEs increased migration and inflammatory responses of adventitial fibroblasts via RAGE, MAPK and NF-κB pathways. Atherosclerosis 28, 34-42 (2010)
27. Sligh JE Jr, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL: Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci USA 90, 8529-33 (1993) (Pubitemid 23277702)
28. Shaw SS, Schmidt AM, Banes AK, Wang X, Stern DM, Marrero MB: S100B-RAGE mediated augmentation of angiotensin II induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2. Diabetes 52, 2381-8 (2003) (Pubitemid 37059510)
29. Wendt T, Bucciarelli L, Qu W, Lu Y, Yan SF, Stern DM, Schmidt AM: Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr Atheroscler Rep 4, 228-37 (2002)
30. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267, 14998-5004 (1992)
31. Ruhs S, Nass N, Somoza V, Friess U, Schinzel R, Silber R, Simm A: Maillard reaction products enriched food extract reduce the expression of myofibroblast phenotype marker. Mol Nutr Food Res 51, 488-495 (2007) (Pubitemid 47083660)
32. Vlassara H, Striker G: Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 7(3), 235-241 (2007) (Pubitemid 46951921)
33. Frye EB, Degenhardt TP, Thorpe SR, Baynes JW: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross links in human lens proteins. J Biol Chem 273 (30), 18714-18719 (1998) (Pubitemid 28366254)
34. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW: The myeloperoxidase system of human phagocytes generates Nepsilon- (carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104 (1), 103-113 (1999) (Pubitemid 29534350)
35. Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R: Aldose reductase and AGERAGE pathways: key players in myocardial ischemic injury. Ann NY Acad Sci 1043, 702-709 (2005) (Pubitemid 41123963)
36. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP: Diabetes associated sustained activation of the transcription factor nuclear factor-kappa B. Diabetes 50, 2792-808 (2001) (Pubitemid 33733131)
37. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, Van Ypersole de Strihou C, Monnier VM, Witztum JL, Kurokawa K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100, 2995-3004 (1997)
38. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G: Advanced Maillard reaction endproducts are associated with Alzheimer disease Pathology. Proc Natl Acad Sci USA 91, 5710-4 (1994) (Pubitemid 24174398)
39. Schleicher E, Wagner E, Nerlich A: Increased accumulation of glycoxidation product carboxymethyllysine in human tissues in diabetes and aging. J Clin Invest 99, 457-68 (1997) (Pubitemid 27414803)
40. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Sido B, Allenberg J, Otto G, Roth H, Bierhaus A, Ziegler R, Schmidt AM, Waldherr R, Wahl P, Stern DM, Nawroth PP: Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol 146, 688-94 (1995)
41. Faist V, Erbersdobler HF: Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 45, 1-12 (2001) (Pubitemid 32221196)
42. Borrelli RC, Fogliano V, Monti SM, Ames JM: Characterization of melanoidins from a glucose-glycine model system. Eur Food Res Technol 215, 210-215 (2002)
43. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99 (24), 15596-15601 (2002) (Pubitemid 35403978)
44. Uribarri J, Stirban A, Sander D, Cai W, Negrean M, Buenting CE, Koschinsky T, Vlassara H: Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30, 2579-2582 (2007) (Pubitemid 47547799)
45. Li W, Sama AE, Wang H: Role of HMGB1 in cardiovascular disease. Curr Opin Pharmacol 6, 130-5 (2006)
46. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248-51 (1999) (Pubitemid 29329996)
47. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, Soejima J, Koh H, Ishizaka A: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170, 1310-6 (2004) (Pubitemid 39657195)
48. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW: A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the committee on vascular lesions of the council on arteriosclerosis, American Heart Association. Circulation 89, 2462-78 (1994) (Pubitemid 24142837)
49. Skålén K, Gustafsson M, Rydberg EK, Hultén LM, Wiklund O, Innerarity TL, Borén J: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417, 750-4 (2002) (Pubitemid 34640629)
50. Leitinger N: Oxidized phospholipids as modulators of inflammation in athersclerosis. Curr Opin Lipidol 14, 421-30 (2003) (Pubitemid 37297296)
51. Dai G, Kaazempur-Mofrad MR, Natarajan S, Zhang Y, Vaughn S, Blackman BR, Kamm RD, García-Cardeña G, Gimbrone MA Jr: Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and resistant regions of human vasculature. Proc Natl Acad Sci USA 101, 14871-6 (2004) (Pubitemid 39410767)
52. Kovanen PT, Kaartinen M, Paavonen T: Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92, 1084-8 (1995)
53. Jones CB, Sane DC, Herrington DM: Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 59, 812-23 (2003) (Pubitemid 38366237)
54. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP: Lysosomal cysteine protease in atherosclerosis. Arterioscler Thromb Vasc Biol 24, 1359-66 (2004)
55. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Fürstenberger G, Müller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P: RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 205 (2), 275-85 (2008) (Pubitemid 351281593)
56. Harja E, Bu D, Hudson BI, Chang JS, Shen X, Hallam K, Kalea AZ, Lu Y, Rosario RH, Oruganti S, Nikolla Z, Belov D, Lalla E, RAmasamy R, Yan SF, Schmidt AM: Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 118, 183-94 (2008)
57. Soro-Paavonen A, Watson AMD, Li J, Paavonen K, Koitka A, Calkin AC, Barit D, Coughlan MT, Drew BG, Lancaster GI, Thomas M, Forbes JM, Nawroth PP, Bierhaus A, Cooper ME, Jandeleit-Dahm KA: Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57, 2461-9 (2008)
58. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4, 1025-31 (1998) (Pubitemid 28417334)
59. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53, 1813-23 (2004) (Pubitemid 38857040)
60. Yao D, Brownlee M: Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE Ligands. Diabetes 59, 249-55 (2010)
61. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology: Management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 24, 28-66 (2003)
62. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJGM: Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 74, 343-55 (2007) (Pubitemid 46693697)
63. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Schmidt AM, Ramasamy R: Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113, 1226-34 (2006)
64. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Hwang YC, Kaneko M, Song F, Sell DR, Strauch C, Monnier VM, Yan SF, Schmidt AM, Ramasamy R: RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 57, 1941-51 (2008)
65. Aleshin A, Ananthakrishnan R, Li Q, Rosario R, Lu Y, Qu W, Song F, Bakr S, Szabolcs M, D'Agati V, Liu R, Homma S, Schmidt AM, Yan SF, Ramasamy R: RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am J Physiol Heart Circ Physiol 294, 1823-32 (2008)
66. Barry SP, Townsend PA, Latchman DS, Stephanou A: Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med 13 (2), 82-9 (2007) (Pubitemid 46201790)
67. Wildhirt SM, Weismueller S, Schulze C, Conrad N, Kornberg A, Reichart B: Inducible nitric oxide synthase activation after ischemia/reperfusion contributes to myocardial dysfunction and extent of infarct size in rabbits: evidence for a late phase of nitric oxidemediated reperfusion injury. Cardiovasc Res 43, 698-711 (1999) (Pubitemid 29369268)
68. Feihl F, Liaudet L, Waeber B: The macrocirculation and microcirculation of hypertension. Curr Hypertens Rep 11, 182-9 (2009)
69. Soldatos G, Cooper ME: Advanced glycation end products and vascular structure and function. Curr Hypertens Rep 8 (6), 472-8 (2006) (Pubitemid 44842773)
70. Versali D, Daghini E, Virdis A, Ghiadoni L, Taddei S: Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 157, 527-36 (2009)
71. Farmer DGS, Kennedy S: RAGE, vascular tone and vascular disease. Pharmacol Ther 124, 185-94 (2009)
72. Gao X, Zhang H, Schmidt AM, Zhang C: AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 295 (2), H491-8 (2008)
73. Hofmann Bowman M, Wilk J, Heydemann A, Kim G, Rehman J, Lodato JA, Raman J, McNally EM: S100A12 Mediates Aortic Wall Remodeling and Aortic Aneurysm. Circ Res 106, 145-54 (2010)
74. Zhang F, Kent KC, Yamanouchi D, Zhang Y, Kato K, Tsai S, Nowygrod R, Schmidt AM, Liu B: Anti- Receptor for Advanced Glycation End Products Therapies as Novel Treatment for Abdominal Aortic Aneurysm. Ann Surg 250, 416-23 (2009)
75. Norton GR, Candy G, Woodiwiss AJ: Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation 93, 1905-12 (1996) (Pubitemid 26154042)
76. Vasan S, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382, 275-8 (1996) (Pubitemid 26251366)
77. Vaitkevicius PV, Lane M, Spurgeon H, Ingram DK, Roth GS, Egan JJ, Vasan S, Wagle DR, Ulrich P, Brines M, Wuerth JP, Cerami A, Lakatta EG: A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 98, 1171-5 (2001) (Pubitemid 32121205)
78. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG: Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464-70 (2001) (Pubitemid 32917336)
79. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Levy BI: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95, 4630-4 (1998)
80. Cooper ME, Thallas V, Forbes J, Scalbert E, Sastra S, Darby I, Soulis T: The cross-link breaker, Nphenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation. Diabetologia 43, 660-4 (2000) (Pubitemid 30322084)
81. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (7), 949-55 (2001) (Pubitemid 32946067)
82. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE/amphoterin suppresses tumor growth and metastases. Nature 405, 354-60 (2000) (Pubitemid 30337069)
83. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716-27 (2008)
84. Bucciarelli LG.,Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, KashyapY, Stern DM, Schmidt AM: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827-35 (2002) (Pubitemid 35396983)
85. Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products. A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84, 489-97 (1999) (Pubitemid 29138585)
86. Hudson BI, Harja E, Moser B, Schmidt AM: Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease. The next C-reactive protein? Arterioscler Thromb Vasc Biol 25, 879-82 (2005) (Pubitemid 40637200)
87. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J: Tissue specific expression patterns of RAGE receptor and its soluble forms-a result of regulated alternative splicing? Biochim Biophys Acta 1630, 1-6 (2003) (Pubitemid 37297971)
88. Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T: Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76, 52-6 (2008)
89. Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T: Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in non diabetic subjects. Metabolism 55, 1227-31 (2006) (Pubitemid 44215942)
90. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49, 2756-62 (2006)
91. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R: Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23, 1725-29 (2005) (Pubitemid 41233433)
92. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D: Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Non diabetic Men. Arterioscler Thromb Vasc Biol 25, 1032-7 (2005) (Pubitemid 40627851)
93. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K, Yamasaki Y: Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204, 288-92 (2009)
94. Nakamura K, Yamagishi S, Adachi H, Kurita- Nakamura Y, Matsui T, Yoshida T, Sato A, Imaizumi T: Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23, 368-71 (2007) (Pubitemid 47091239)
95. Nakamura K, Yamagishi S, Adachi H, Kurita- Nakamura Y, Matsui T, Yoshida T, Imaizumi T: Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes. Mol Med 13, 185-9 (2007) (Pubitemid 46944961)
96. Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, Bierhaus A: Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6, 9 (2007)
97. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y: Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25, 2587-93 (2005) (Pubitemid 43732283)
98. Geroldi D, Falcone C, Emanuele E: Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13, 1971-8 (2006)
99. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405, 354-60 (2000) (Pubitemid 30337069)
100. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C, Stern A, LaFaille J, Chess L, Stern DM, Jiang H: Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9, 287-93 (2003) (Pubitemid 36362783)
101. Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF: RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. Atherosclerosis 185, 70-7 (2006) (Pubitemid 43117552)
102. Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, Arnold B, Nawroth PP, Yan SF, D'Agati V, Schmidt AM: Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 14, 1383-95 (2003). (Pubitemid 36514678)
103. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820 (2001) (Pubitemid 34000785)
104. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, Topol EJ: Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation 107(25), 2238-2243 (2003) (Pubitemid 36547219)
105. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM: Neointimal hyperplasia following arterial injury is increased in rat model of non insulin dependent diabetes mellitus. Circulation 104, 815-819 (2001) (Pubitemid 32762681)
106. Cazalla D, Sanford JR, Cáceres JF: A rapid and efficient protocol to purify biologically active recombinant protein from mammalian cells. Protein Expr Purif 42, 54-58 (2005) (Pubitemid 40793393)